<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Although [(18)F]fluorothymidine <z:chebi fb="4" ids="30225">positron</z:chebi> emission tomography (FLT-PET) permits estimation of <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> <z:chebi fb="0" ids="17748">thymidine</z:chebi> kinase-1 expression, and thus, cell proliferation, high physiological uptake of tracer in liver tissue can limit its utility </plain></SENT>
<SENT sid="1" pm="."><plain>We evaluated FLT-PET combined with a temporal-intensity information-based voxel-clustering approach termed kinetic spatial filtering (FLT-PET(KSF)) for detecting drug response in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>FLT-PET and computed tomography data were collected from patients with confirmed breast or colorectal <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> before, and two weeks after the first cycle of chemotherapy </plain></SENT>
<SENT sid="3" pm="."><plain>Changes in <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> FLT-PET and FLT-PET(KSF) variables were determined </plain></SENT>
<SENT sid="4" pm="."><plain>Visual distinction between <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> and <z:mpath ids='MPATH_458'>normal</z:mpath> liver was seen in FLT-PET(KSF) images </plain></SENT>
<SENT sid="5" pm="."><plain>Of the 33 metastases from 20 patients studied, 26 were visible after kinetic filtering </plain></SENT>
<SENT sid="6" pm="."><plain>The net irreversible retention of the tracer (Ki; from unfiltered data) in the <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e>, correlated strongly with tracer uptake when the imaging variable was an unfiltered average or maximal standardized uptake value, 60 min post-injection (SUV(60,av): r = 0.9, SUV(60,max): r = 0.7; p &lt; 0.0001 for both) and occurrence of high intensity voxels derived from FLT-PET(KSF) (r = 0.7, p &lt; 0.0001) </plain></SENT>
<SENT sid="7" pm="."><plain>Overall, a significant reduction in the imaging variables was seen in responders compared to non-responders; however, the two week time point selected for imaging was too early to allow prediction of long term clinical benefit from chemotherapy </plain></SENT>
<SENT sid="8" pm="."><plain>FLT-PET and FLT-PET(KSF) detected changes in proliferation in <z:e sem="disease" ids="C0494165" disease_type="Neoplastic Process" abbrv="">liver metastases</z:e> </plain></SENT>
</text></document>